Pooling Medicine has been deeply engaged in translational medicine and clinical research consulting for over a decade, bringing together clinical medicine experts, basic medicine experts, and biomedical science & technology experts. Our services cover translational medicine, IIT (investigator-initiated trials), IND submission and Phase I / II / III / IV clinical trials, post-marketing clinical research, and CGT (cell and gene therapy). We provide high-quality medical expert interviews and medical consulting services for VC, PE and angel investment institutions, drug R&D companies, and strategy & business development departments of biopharmaceutical companies — from investment due diligence to clinical development, helping you turn uncertainty into decision-ready insight.
PoolingMed has spent over a decade focused on translational medicine and clinical research consulting, drawing on clinical medicine experts, basic medical scientists, and biopharmaceutical science & technology experts. Our services cover translational medicine, investigator-initiated trials (IIT), IND filings and Phase I / II / III / IV clinical trials, post-marketing studies, and cell & gene therapy (CGT) — serving VC / PE / angel investors, drug developers and strategy teams of biopharma companies, from investment diligence to clinical development.
Explore Expert Consulting Expert Consulting 中文版首页 · Chinese Site →For VC / PE / angel investment institutions, drug R&D companies, and strategy & business development departments of biopharmaceutical companies, covering the full lifecycle from target discovery to post-marketing research — from laboratory discovery to clinical validation, from IND submission to trials at each phase, from registration to real-world evidence.
For VC / PE / angel investors, drug developers and strategy teams — covering the full lifecycle from target discovery to post-marketing: bench-to-clinic translation, IND filings, Phase I–IV trials, and real-world evidence.
Directors of core research centers and leading KOLs in key departments such as oncology, autoimmune and metabolic diseases, serving as first-line investigators across all phases of clinical trials.Leading investigators and key opinion leaders at China's core research centers — frontline clinical trial experience across Phase I–IV.
PIs and translational research teams from medical universities and research institutes, providing in-depth scientific argumentation from mechanism research to proof of concept.PIs and translational research teams from medical universities and institutes — deep scientific validation from mechanism studies to proof of concept.
Senior experts from pharma R&D, CXOs and technology platforms, with engineering and industry experience in CMC, drug-device combinations, CGT and other frontier areas.Senior experts from pharma R&D, CXOs and technology platforms — engineering and industry experience across CMC, drug-device combinations and CGT.
Laboratory discovery → clinical validation pathway
Bench discovery → clinical validation
Preclinical evidence review & regulatory pathway
Preclinical evidence & regulatory path
First-in-human · PK & tolerability
First-in-human · PK & tolerability
Pivotal trial design & evidence generation
Pivotal trial design & evidence
Post-marketing studies & real-world evidence
Post-marketing & real-world evidence
From laboratory discovery to clinical validation: biomarker strategy, translational study design, proof-of-concept (PoC) pathways and interdisciplinary expert argumentation.Bench-to-clinic translation: biomarker strategy, translational study design, proof-of-concept pathways and cross-disciplinary expert validation.
Pre-IND evidence review and regulatory pathway discussion; medical consulting and expert argumentation for Phase I trials (first-in-human, dose escalation, PK/PD).Pre-IND evidence synthesis and regulatory pathway discussion; medical consulting for Phase I trials (first-in-human, dose escalation, PK/PD).
Medical consulting on indication and endpoint selection, protocol design review, investigator resources and site strategy for pivotal trials.Medical consulting for pivotal trials: indication and endpoint selection, protocol design review, investigator and site strategy.
Design consulting for post-marketing studies and real-world studies (RWS), indication expansion argumentation, and medical support for pharmacovigilance.Design consulting for post-marketing and real-world studies (RWS), label-expansion rationale and pharmacovigilance-related medical support.
Study design optimization, feasibility assessment, compliance pathways and site/investigator matching for IITs — built on more than a decade of first-line project experience.IIT protocol optimization, feasibility assessment, compliance pathways and site/investigator matching — a decade of hands-on experience.
Translational assessment of cell and gene therapy programs, key trial design considerations, and consulting on China's regulatory and research center landscape.Translational assessment of cell & gene therapy programs, trial-design considerations, and the Chinese regulatory and site landscape.
For angel-round investors and innovative technology patent transactions: independent wet-lab validation and reproduction of key data and technical parameters of the target technology, with professional validation reports — so that investment and transaction decisions are built on verifiable experimental evidence.For angel-round investors and innovative technology / patent transactions: independent wet-lab validation and replication of key data and technical parameters of the target technology, delivered with a professional validation report — so investment and deal decisions rest on verifiable experimental evidence.
When AI compresses drug discovery to the scale of 'hours', the real bottleneck shifts to validation — wet-lab and clinical validation still take 'months to years', and AI-designed molecules show roughly twice the industry-baseline Phase I success rate while Phase II remains on par with the industry. With more than a decade of wet-lab and clinical research experience, Pooling Medicine provides 'dry-wet closed loop' translational medicine consulting for AI for Science teams, investors and innovative technology holders: hypotheses are raised computationally, validated and reproduced in wet labs, and 'intervention-phenotype' data flows back into the models.
AI has compressed drug discovery to hours — but validation still takes months to years, and while AI-designed molecules double Phase I success rates, Phase II remains flat. The bottleneck has moved to the wet lab. Drawing on a decade of hands-on wet-lab and clinical research capability, PoolingMed provides "dry-wet closed-loop" translational consulting for AI-for-Science teams, investors and technology holders: hypotheses proposed by computation, validated and replicated in the wet lab, with interventional-phenotype data flowing back into the models.
Wet-lab validation study design for AI model predictions: experimental validation and data reproduction of molecules, targets and mechanisms, producing 'intervention-phenotype' data assets that flow back into models.Wet-lab validation protocols for model predictions: experimental verification and data replication for molecules, targets and mechanisms — producing interventional-phenotype data assets that feed back into models.
Assessing the translational value of AI-designed molecules and targets: druggability judgment, indication selection, PoC pathways, and IND / IIT transition consulting — the sober perspective that 'Phase I doubles, Phase II is the touchstone'.Assessing the translational value of AI-designed molecules and targets: druggability, indication selection, PoC pathways and IND / IIT routes — with the sober view that Phase II, not Phase I, is the touchstone.
An expert team led by Dr. Lei Guo, CEO / CSO of Pooling Medicine (formerly Professor of Pathophysiology at Zhejiang University School of Medicine and postdoctoral fellow in the Department of Genetics at Harvard Medical School), provides AI for Science trend analysis and evaluative argumentation of forward-looking research directions (including original hypotheses such as 'The Biology of Wavism').A scientific advisory team led by Dr. Lei Guo (PoolingMed CEO/CSO; formerly Professor of Pathophysiology at Zhejiang University School of Medicine and postdoctoral fellow at Harvard Medical School), providing trend analysis and assessment of forward-looking original research directions.
Theory and practice output: Dr. Lei Guo, CEO / CSO of Pooling Medicine, has been invited to give a keynote speech — 'AI for Science: Status, Future and Core Questions' — at the AI for Science Forum of the 4th CCF Conference on Digital Medicine.Thought leadership: Dr. Lei Guo, PoolingMed CEO / CSO, delivered the keynote "AI for Science: Status, Future and Core Questions" at the AI for Science Forum of the 4th CCF Digital Medicine Conference.
We don't chase the size of our expert database. What is truly scarce is the professional judgment, expert relationships and project know-how built through long-term focus in niche clinical research areas.
We don't compete on database size. What is genuinely scarce is the judgment, the expert relationships and the project know-how built from years of hands-on work in clinical research.
We are not a 'do-everything' general consulting firm. For over a decade, Pooling has focused only on translational medicine and clinical research consulting — focus itself is our greatest differentiation, and it brings professional judgment across therapeutic areas and development stages.We are not a generalist consulting firm. For more than ten years, PoolingMed has worked exclusively in translational medicine and clinical research consulting. That singular focus compounds into cross-therapeutic-area, cross-stage judgment.
Leveraging first-line expert relationships accumulated through a decade of clinical research collaboration, we can rapidly organize high-quality expert interviews in key areas such as oncology, autoimmune, metabolic and CGT — covering core research centers and leading clinical experts, not just generic 'industry insiders'.Years of hands-on clinical research collaboration have built first-line expert relationships across oncology, immunology, metabolic disease and CGT — enabling rapid access to leading investigators at China's core research centers.
Unlike generic expert networks, the Pooling team has medical and research backgrounds: we understand your scientific questions, design interview guides in professional language, and cross-validate expert opinions — delivering decision-supporting insights, not just call records.Unlike generalist networks, our team has medical and scientific training. We understand your scientific questions, design interview guides in the right language, and validate expert input — delivering decision-ready insight, not just call logs.
The following typical engagement scenarios are summarized from real-world requirement types to illustrate how we work and the value we deliver.
Typical engagement scenarios illustrating how we work and what we deliver, based on recurring client needs.
Evaluating a clinical-stage Chinese innovative drug asset requires verifying its scientific hypothesis, the quality of clinical data, and the real risks of the China regulatory pathway.A clinical-stage Chinese drug asset must be validated: scientific hypothesis, quality of clinical data, and the true regulatory risk in China.
Assess the IND submission feasibility, Phase I design considerations, and China market competitive landscape of a candidate drug.Assess IND readiness, Phase I design considerations and the Chinese competitive landscape for a new candidate.
A marketed product needs Phase IV studies and real-world evidence to support indication expansion and market access.A marketed product needed Phase IV studies and real-world evidence to support label expansion and market access.
Pooling Medicine is an AI for Science medical research collaboration organization, providing hospitals, universities and pharmaceutical companies with medical research consulting, translational medicine consulting, clinical research consulting, CGT co-innovation and translation collaboration services, and CGT project incubation.
Pooling Medicine is an AI for Science medical research collaboration organization, providing medical research consulting, translational medicine consulting and clinical research consulting, together with CGT co-innovation & translation partnership services and CGT project incubation.
Scope and boundaries: Pooling Medicine provides research and translation consulting services and collaborative innovation partnerships; it does not directly provide clinical care, nor is it a CRO/CDMO contract manufacturer. CGT project incubation refers to collaborative incubation of research results toward industrialization and involves no external fundraising commitments. Coverage includes refractory and relapsing disease areas such as oncology, fibrosis, immune dysregulation and aging.
Last updated: 2026-11-21 · Source: Pooling Medicine official website (www.poolingmed.com)
Details of the five business lines: Medical Research Consulting · Translational Medicine Consulting · Clinical Research Consulting · CGT Co-innovation & Translation Collaboration · CGT Project Incubation · Services Overview & FAQ
Technology platforms and business systems accumulated over a decade — translational R&D, corporate academic services, hospital department services and curated reagent marketplace.
A decade of accumulated platforms and business lines — translational R&D, corporate academic services, hospital department services and a reagent marketplace.
Our clients all face the same problem: major decisions require a genuine, professional Chinese clinical perspective.Our clients share one problem: consequential decisions that need a real, professional view from China's clinical community.
Clinical expert interview needs during investment research and portfolio management; pre-investment due diligence and sector assessment.Expert interviews for investment research — diligence and sector evaluation.
Medical consulting needs in IND submission, clinical trial design at each phase, and registration strategy.Medical consulting for IND filings, trial design and regulatory strategy.
Medical evidence review and expert opinion validation for BD and pipeline decisions.Evidence synthesis and expert validation for BD and pipeline decisions.
Tell us about the asset you are evaluating, the decision you face, or the study you plan to conduct. We will respond within one business day and start the collaboration under an NDA.
Tell us the asset you are evaluating, the decision you face, or the study you plan. We reply within one business day and sign an NDA before any engagement.
Tel: +86 186 5713 3850 · WeChat: XJXJace
All consultations are conducted under NDA by default.
All engagements are conducted under NDA by default.